DocGo Inc. (NASDAQ:DCGO) Director Purchases $22,350.00 in Stock

DocGo Inc. (NASDAQ:DCGO) Director Stephen K. M.D. Klasko bought 15,000 shares of the firm’s stock in a transaction dated Wednesday, May 14th. The shares were bought at an average price of $1.49 per share, with a total value of $22,350.00. Following the completion of the transaction, the director now directly owns 15,000 shares in the company, valued at approximately $22,350. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

DocGo Stock Performance

Shares of DCGO opened at $1.40 on Friday. DocGo Inc. has a twelve month low of $1.35 and a twelve month high of $5.68. The firm’s 50 day moving average price is $2.39 and its two-hundred day moving average price is $3.63. The firm has a market cap of $142.78 million, a P/E ratio of 5.00, a PEG ratio of 14.16 and a beta of 1.14.

DocGo (NASDAQ:DCGO) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.08). The company had revenue of $96.03 million for the quarter, compared to analyst estimates of $104.25 million. DocGo had a return on equity of 8.90% and a net margin of 4.35%. On average, sell-side analysts anticipate that DocGo Inc. will post 0.25 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

DCGO has been the topic of several recent analyst reports. Stifel Nicolaus reduced their price objective on shares of DocGo from $6.50 to $5.50 and set a “buy” rating on the stock in a research note on Friday, February 28th. Canaccord Genuity Group reissued a “hold” rating and set a $1.45 price target (down from $5.00) on shares of DocGo in a research report on Monday. Deutsche Bank Aktiengesellschaft lowered shares of DocGo from a “buy” rating to a “hold” rating and decreased their price target for the company from $5.00 to $2.85 in a report on Friday, February 28th. Needham & Company LLC dropped their price objective on DocGo from $4.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Finally, BTIG Research cut DocGo from a “buy” rating to a “neutral” rating in a research note on Friday, May 9th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, DocGo presently has a consensus rating of “Moderate Buy” and an average price target of $3.56.

Hedge Funds Weigh In On DocGo

A number of large investors have recently added to or reduced their stakes in DCGO. Summit Securities Group LLC bought a new stake in shares of DocGo in the first quarter valued at about $34,000. Summit Investment Advisors Inc. raised its position in DocGo by 38.7% in the 4th quarter. Summit Investment Advisors Inc. now owns 10,639 shares of the company’s stock valued at $45,000 after buying an additional 2,968 shares during the last quarter. Prudential Financial Inc. bought a new stake in DocGo in the 4th quarter valued at approximately $55,000. Royce & Associates LP bought a new stake in DocGo in the 4th quarter valued at approximately $64,000. Finally, Boothbay Fund Management LLC boosted its position in DocGo by 154.9% during the 4th quarter. Boothbay Fund Management LLC now owns 27,445 shares of the company’s stock worth $116,000 after acquiring an additional 77,445 shares during the last quarter. Institutional investors own 56.44% of the company’s stock.

DocGo Company Profile

DocGo Inc provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services.